{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T16:23:29Z","timestamp":1790871809474,"version":"4.1.0"},"reference-count":104,"publisher":"Informa UK Limited","issue":"12","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Expert Opinion on Investigational Drugs"],"published-print":{"date-parts":[[2010,12]]},"DOI":"10.1517\/13543784.2010.535515","type":"journal-article","created":{"date-parts":[[2010,11,13]],"date-time":"2010-11-13T05:18:30Z","timestamp":1289625510000},"page":"1591-1602","source":"Crossref","is-referenced-by-count":33,"title":["Afamelanotide, an agonistic analog of \u03b1-melanocyte-stimulating hormone, in dermal phototoxicity of erythropoietic protoporphyria"],"prefix":"10.1517","volume":"19","author":[{"given":"Elisabeth I","family":"Minder","sequence":"first","affiliation":[{"name":"Stadtspital Triemli, Central Laboratory, Zurich, CH-8063, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"301","published-online":{"date-parts":[[2010,11,13]]},"reference":[{"key":"e_1_3_1_2_1","first-page":"2991","volume-title":"The metabolic and molecular basis of inherited disease","author":"Anderson K","year":"2001","unstructured":"Anderson K, Sassa S, Bishop DF, Desnick RJ. Disorders of heme biosynthesis: X-linked sideroblastic anemia and the porphyrias. In: Scriver CR, Beaugrand M, Sly WS, Valle D, editors, The metabolic and molecular basis of inherited disease. 8th edition. McGraw-Hill, New York; 2001. p. 2991-3062","edition":"8"},{"key":"e_1_3_1_3_1","doi-asserted-by":"publisher","DOI":"10.1007\/s004310000494"},{"key":"e_1_3_1_4_1","doi-asserted-by":"publisher","DOI":"10.1186\/1750-1172-4-19"},{"key":"e_1_3_1_5_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1469-1809.1984.tb01006.x"},{"key":"e_1_3_1_6_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2133.2010.09631.x"},{"key":"e_1_3_1_7_1","doi-asserted-by":"publisher","DOI":"10.1038\/ng809"},{"key":"e_1_3_1_8_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajhg.2008.08.003"},{"key":"e_1_3_1_9_1","doi-asserted-by":"publisher","DOI":"10.1172\/JCI108233"},{"key":"e_1_3_1_10_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1751-1097.1990.tb01967.x"},{"key":"e_1_3_1_11_1","doi-asserted-by":"publisher","DOI":"10.3181\/00379727-127-32829"},{"key":"e_1_3_1_12_1","doi-asserted-by":"publisher","DOI":"10.1590\/S0100-879X1999000300002"},{"key":"e_1_3_1_13_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(61)92427-8"},{"key":"e_1_3_1_14_1","doi-asserted-by":"publisher","DOI":"10.1562\/0031-8655(2000)072<0186:POAAIP>2.0.CO;2"},{"key":"e_1_3_1_15_1","doi-asserted-by":"publisher","DOI":"10.1172\/JCI106884"},{"key":"e_1_3_1_16_1","doi-asserted-by":"publisher","DOI":"10.1111\/1523-1747.ep12479191"},{"key":"e_1_3_1_17_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1749-6632.1985.tb11823.x"},{"key":"e_1_3_1_18_1","doi-asserted-by":"publisher","DOI":"10.1067\/mjd.2000.107498"},{"key":"e_1_3_1_19_1","first-page":"671","article-title":"Mechanisms of phototoxicity in porphyria cutanea tarda and erythropoietic protoporphyria","volume":"46","author":"Lim HW","year":"1989","unstructured":"Lim HW. Mechanisms of phototoxicity in porphyria cutanea tarda and erythropoietic protoporphyria. Immunol Ser 1989;46:671-85","journal-title":"Immunol Ser"},{"key":"e_1_3_1_20_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.0022-202X.2004.23531.x"},{"key":"e_1_3_1_21_1","first-page":"339","article-title":"\u201c... and found no shade\u201d. Coping processes of patients with erythropoietic protoporphyria","volume":"42","author":"Rufener EA","year":"1992","unstructured":"Rufener EA. \u201c... and found no shade\u201d. Coping processes of patients with erythropoietic protoporphyria. Psychother Psychosom Med Psychol 1992;42:339-48","journal-title":"Psychother Psychosom Med Psychol"},{"key":"e_1_3_1_22_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2133.1987.tb05904.x"},{"key":"e_1_3_1_23_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2133.2008.08581.x"},{"key":"e_1_3_1_24_1","doi-asserted-by":"publisher","DOI":"10.1002\/lt.21527"},{"key":"e_1_3_1_25_1","first-page":"84","article-title":"A systematic review of treatment options for dermal photosensitivity in erythropoietic protoporphyria","volume":"55","author":"Minder EI","year":"2009","unstructured":"Minder EI, Schneider-Yin X, Steuer J, Bachmann LM. A systematic review of treatment options for dermal photosensitivity in erythropoietic protoporphyria. Cell Mol Biol (Noisy-le-grand) 2009;55:84-97","journal-title":"Cell Mol Biol (Noisy-le-grand)"},{"key":"e_1_3_1_26_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2133.1977.tb14273.x"},{"key":"e_1_3_1_27_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2133.2006.07472.x"},{"key":"e_1_3_1_28_1","unstructured":"Wahlin S Floderus Y Stal P Harper P. Erythropoietic protoporphyria in Sweden: demographic clinical biochemical and genetic characteristics. J Intern Med 2010: published online 13 March 2010 DOI: 10.1111\/j.1365-2796.2010. 02236.x"},{"key":"e_1_3_1_29_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2133.1995.tb16955.x"},{"key":"e_1_3_1_30_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2133.2006.07471.x"},{"key":"e_1_3_1_31_1","unstructured":"Rufener EA. Schattenspringen; Krankheitsanpassung bei Menschen mit einer erythropoetischen Protoporphyrie. 1-386. 1990. Universitat Zurich Philosophische Fakultat I. (Thesis\/Dissertation)"},{"key":"e_1_3_1_32_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.0022-202X.2004.23529.x"},{"key":"e_1_3_1_33_1","doi-asserted-by":"publisher","DOI":"10.1038\/10488"},{"key":"e_1_3_1_34_1","doi-asserted-by":"publisher","DOI":"10.1067\/mjd.2002.120460"},{"key":"e_1_3_1_35_1","doi-asserted-by":"publisher","DOI":"10.1542\/peds.2006-0833"},{"key":"e_1_3_1_36_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2006.10.004"},{"key":"e_1_3_1_37_1","doi-asserted-by":"publisher","DOI":"10.1038\/bjc.1979.165"},{"key":"e_1_3_1_38_1","doi-asserted-by":"publisher","DOI":"10.1038\/bjc.1979.260"},{"key":"e_1_3_1_39_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(02)09779-9"},{"key":"e_1_3_1_40_1","doi-asserted-by":"publisher","DOI":"10.1093\/hmg\/10.21.2397"},{"key":"e_1_3_1_41_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.peptides.2004.12.032"},{"key":"e_1_3_1_42_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.mrfmmm.2004.09.014"},{"key":"e_1_3_1_43_1","doi-asserted-by":"publisher","DOI":"10.1146\/annurev.genet.37.110801.143233"},{"key":"e_1_3_1_44_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1749-6632.2003.tb03199.x"},{"key":"e_1_3_1_45_1","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1111\/j.1749-6632.2003.tb03198.x","article-title":"Defining the quantitative contribution of the melanocortin 1 receptor (MC1R) to variation in pigmentary phenotype","volume":"994","author":"Ha T","year":"2003","unstructured":"Ha T, Naysmith L, Waterston K, Defining the quantitative contribution of the melanocortin 1 receptor (MC1R) to variation in pigmentary phenotype. Ann NY Acad Sci 2003;994:339-47","journal-title":"Ann NY Acad Sci"},{"key":"e_1_3_1_46_1","doi-asserted-by":"publisher","DOI":"10.1038\/ng1195-328"},{"key":"e_1_3_1_47_1","doi-asserted-by":"crossref","unstructured":"Nordlund JJ Boissy RE Haering VJ The pigmentary system: physiology and pathophysiology. 2nd edition. Blackwell Publishing Ltd Malden Massachusetts; 2006","DOI":"10.1002\/9780470987100"},{"key":"e_1_3_1_48_1","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.M406334200"},{"key":"e_1_3_1_49_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1755-148X.2009.00615.x"},{"key":"e_1_3_1_50_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1751-1097.1996.tb02988.x"},{"key":"e_1_3_1_51_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2006.12.045"},{"key":"e_1_3_1_52_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMcibr071775"},{"key":"e_1_3_1_53_1","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.M202939200"},{"key":"e_1_3_1_54_1","doi-asserted-by":"publisher","DOI":"10.1038\/sj.jid.5700421"},{"key":"e_1_3_1_55_1","doi-asserted-by":"publisher","DOI":"10.1086\/302711"},{"key":"e_1_3_1_56_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pgen.0030009"},{"key":"e_1_3_1_57_1","doi-asserted-by":"publisher","DOI":"10.1038\/jid.2010.48"},{"key":"e_1_3_1_58_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1755-148X.2009.00598.x"},{"key":"e_1_3_1_59_1","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-09-4596"},{"key":"e_1_3_1_60_1","doi-asserted-by":"publisher","DOI":"10.1210\/en.2008-1315"},{"key":"e_1_3_1_61_1","doi-asserted-by":"publisher","DOI":"10.1210\/er.2006-0034"},{"key":"e_1_3_1_62_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0014-2999(99)00298-8"},{"key":"e_1_3_1_63_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.peptides.2005.01.029"},{"key":"e_1_3_1_64_1","doi-asserted-by":"publisher","DOI":"10.2741\/1958"},{"key":"e_1_3_1_65_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0021-9258(18)53088-X"},{"key":"e_1_3_1_66_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0021-9258(18)82452-8"},{"key":"e_1_3_1_67_1","doi-asserted-by":"publisher","DOI":"10.1210\/en.2008-1212"},{"key":"e_1_3_1_68_1","doi-asserted-by":"publisher","DOI":"10.1093\/hmg\/ddm177"},{"key":"e_1_3_1_69_1","doi-asserted-by":"publisher","DOI":"10.1002\/humu.20788"},{"key":"e_1_3_1_70_1","doi-asserted-by":"publisher","DOI":"10.1038\/509"},{"key":"e_1_3_1_71_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-0749.1989.tb00248.x"},{"key":"e_1_3_1_72_1","first-page":"1691","article-title":"Studies on factors influencing human plasma alpha-MSH","volume":"9","author":"Ghanem G","year":"1989","unstructured":"Ghanem G, Verstegen J, De Rijcke S, Studies on factors influencing human plasma alpha-MSH. Anticancer Res 1989;9:1691-6","journal-title":"Anticancer Res"},{"key":"e_1_3_1_73_1","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2133.1998.02263.x"},{"key":"e_1_3_1_74_1","doi-asserted-by":"publisher","DOI":"10.1038\/308544a0"},{"key":"e_1_3_1_75_1","doi-asserted-by":"publisher","DOI":"10.1097\/00008390-199205000-00002"},{"key":"e_1_3_1_76_1","first-page":"3239","article-title":"Increased experimental metastatic capacity of a murine melanoma following induction of differentiation","volume":"46","author":"Bennett DC","year":"1986","unstructured":"Bennett DC, Dexter TJ, Ormerod EJ, Hart IR. Increased experimental metastatic capacity of a murine melanoma following induction of differentiation. Cancer Res 1986;46:3239-44","journal-title":"Cancer Res"},{"key":"e_1_3_1_77_1","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.92.5.1789"},{"key":"e_1_3_1_78_1","first-page":"82","article-title":"Alpha-melanocyte-stimulating hormone blocks invasion of reconstituted basement membrane (Matrigel) by murine B16 melanoma cells","volume":"17","author":"Murata J","year":"1997","unstructured":"Murata J, Ayukawa K, Ogasawara M, Alpha-melanocyte-stimulating hormone blocks invasion of reconstituted basement membrane (Matrigel) by murine B16 melanoma cells. Invasion Metastasis 1997;17:82-93","journal-title":"Invasion Metastasis"},{"key":"e_1_3_1_79_1","doi-asserted-by":"publisher","DOI":"10.1038\/sj.bjc.6601349"},{"key":"e_1_3_1_80_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.peptides.2005.01.027"},{"key":"e_1_3_1_81_1","doi-asserted-by":"publisher","DOI":"10.1038\/sj.bjc.6603283"},{"key":"e_1_3_1_82_1","doi-asserted-by":"publisher","DOI":"10.1242\/dev.02161"},{"key":"e_1_3_1_83_1","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-05-1343"},{"key":"e_1_3_1_84_1","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-04-2970"},{"key":"e_1_3_1_85_1","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-04-3327"},{"key":"e_1_3_1_86_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-0749.1995.tb00680.x"},{"key":"e_1_3_1_87_1","doi-asserted-by":"publisher","DOI":"10.1002\/(SICI)1099-081X(199704)18:3<259::AID-BDD20>3.0.CO;2-X"},{"key":"e_1_3_1_88_1","doi-asserted-by":"publisher","DOI":"10.1023\/A:1007525117894"},{"key":"e_1_3_1_89_1","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.77.10.5754"},{"key":"e_1_3_1_90_1","doi-asserted-by":"publisher","DOI":"10.1006\/bbrc.1994.2067"},{"key":"e_1_3_1_91_1","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.272.37.23000"},{"key":"e_1_3_1_92_1","doi-asserted-by":"publisher","DOI":"10.1096\/fj.05-5655fje"},{"key":"e_1_3_1_93_1","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-04-4535"},{"key":"e_1_3_1_94_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.peptides.2004.11.031"},{"key":"e_1_3_1_95_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.peptides.2004.12.038"},{"key":"e_1_3_1_96_1","doi-asserted-by":"publisher","DOI":"10.1038\/sj.jid.5700317"},{"key":"e_1_3_1_97_1","doi-asserted-by":"publisher","DOI":"10.1358\/dof.2010.035.05.1484387"},{"key":"e_1_3_1_98_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMc0805682"},{"key":"e_1_3_1_99_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1751-1097.2009.00595.x"},{"key":"e_1_3_1_100_1","unstructured":"Minder EI Harms J Lautenschlager S A double-blind randomized controlled Phase III trial of afamelanotide (an alpha-MSH analogue) in erythropoietic protoporphyria (EPP) \u2013 preliminary data on a Swiss cohort of patients and a model to determine efficacy in EPP [abstract]. Berzelius symposium 81- Porphyrins and Porphyrias (14 \u2013 18 June Stockholm) 2009: abstract O09. Available from: http:\/\/www.svls.se\/cs-media\/xyz\/bz81final.pdf [Last accessed 29 October 2010]"},{"key":"e_1_3_1_101_1","doi-asserted-by":"publisher","DOI":"10.1186\/1477-7525-8-60"},{"key":"e_1_3_1_102_1","unstructured":"Preliminary results in Clinuvel's Phase III porphyria trial. Melbourne Australia: Clinuvel Pharmaceuticals Ltd. 2009. Available from: http:\/\/clinuvel.com\/resources\/cmsfiles\/pdf\/20091221EPPPrelim.pdf [Last accessed 30 October 2010]"},{"key":"e_1_3_1_103_1","unstructured":"Clinuvel reports positive results in phase III porphria (EPP) clinical trial. Melbourne Australia: Clinuvel Pharmaceuticals Ltd. 2020. Available from: http:\/\/clinuvel.com\/resources\/cmsfiles\/pdf\/20100713CUV017Results.pdf [Last accessed 22 October 2010]"},{"key":"e_1_3_1_104_1","doi-asserted-by":"publisher","DOI":"10.1517\/13543776.11.1.61"},{"key":"e_1_3_1_105_1","doi-asserted-by":"publisher","DOI":"10.1016\/0024-3205(96)00370-0"}],"container-title":["Expert Opinion on Investigational Drugs"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.1517\/13543784.2010.535515","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T10:07:27Z","timestamp":1756721247000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.tandfonline.com\/doi\/full\/10.1517\/13543784.2010.535515"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,11,13]]},"references-count":104,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2010,12]]}},"alternative-id":["10.1517\/13543784.2010.535515"],"URL":"https:\/\/doi.org\/10.1517\/13543784.2010.535515","relation":{},"ISSN":["1354-3784","1744-7658"],"issn-type":[{"value":"1354-3784","type":"print"},{"value":"1744-7658","type":"electronic"}],"subject":[],"published":{"date-parts":[[2010,11,13]]}}}